<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04387617</url>
  </required_header>
  <id_info>
    <org_study_id>19-011832</org_study_id>
    <nct_id>NCT04387617</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Effect of Cannabidiol Oil on Pain After Ureteroscopy for Kidney Stones</brief_title>
  <official_title>Effect of Cannabidiol Oil on Postoperative Pain After Ureteroscopy for Urinary Calculi</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if CBD oil has any effect on decreasing
      postoperative pain control following ureteroscopy for urinary stone disease, and to determine
      if CBD oil has any effect in decreasing the amount of postoperative opioids (commonly used
      drug) used by patients after undergoing ureteroscopy for urinary stone disease.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post operative Pain intensity</measure>
    <time_frame>3 days post-ureteroscopy</time_frame>
    <description>Patient self-reported pain intensity score using a 100 mm visual analog scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative opioid use</measure>
    <time_frame>3 days post-ureteroscopy</time_frame>
    <description>Total dosage of opioids used by patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ureteric stent symptoms</measure>
    <time_frame>1 and 3 days post-ureteroscopy</time_frame>
    <description>Ureteric stent Symptoms Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects and adverse events</measure>
    <time_frame>3 days post-ureteroscopy</time_frame>
    <description>post operative adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Urinary Stone</condition>
  <arm_group>
    <arm_group_label>CBD Oil Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabidiol</intervention_name>
    <description>The product is a liquid formulation that will be prescribed at a dosage of 20 mg per day for a total of 3 days.</description>
    <arm_group_label>CBD Oil Group</arm_group_label>
    <other_name>Epidiolex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The product is a liquid formulation placebo that will be prescribed at an equivalent volume as active drug for 3 days</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are diagnosed with kidney or ureteral stones confirmed on imaging (CT of
             the abdomen and pelvis) and who elect for definitive treatment via ureteroscopy at two
             sites within a tertiary care institution.

          -  Age 18-75 years of age.

          -  Patients of either gender.

          -  Patients of all ethnic backgrounds.

          -  Capable of giving informed consent.

          -  Capable and willing to fulfill the requirements of the study.

        Exclusion Criteria:

          -  History of chronic pain.

          -  Chronic use of opioid or other pain medication (&gt; 12 weeks).

          -  Known allergy to CBD oil or other cannabinoids.

          -  Known or suspected pregnancy.

          -  Inability to give informed consent or unable to meet requirements of the study for any
             reason.

          -  Bilateral ureteroscopy.

          -  Current marijuana, cannabidiol (CBD), or dronabinol use.

          -  Liver disease/cirrhosis.

          -  Current treatment of seizures with clobazam, valproate, or other antiepileptic
             medications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Stern, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 11, 2020</study_first_submitted>
  <study_first_submitted_qc>May 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2020</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Karen L. Stern</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Calculi</mesh_term>
    <mesh_term>Urolithiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epidiolex</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

